Scinovex
articleTop 1% cited

Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis

Thrombosis and Haemostasis · 1987 · Vol. 57(01) · pp. 067–072

Abstract

The fibrinolytic system was investigated in 120 patients with spontaneous or recurrent deep vein thrombosis (DVT) without any known organic disease able to explain by itself the occurrence of a thrombosis and without any known defect of antithrombin III, Heparin Cofactor II, Protein C, or Protein S. The assays included: Euglobulin fibrinolytic activity (EFA), tissue-type plasminogen activator related antigen (t-PA-Ag) and plasminogen activator inhibitor activity (PA inhibitor), which were measured before and after 10 min of venous occlusion (V.O.). On the basis of the results, the patients could be classified in 3 groups: good responders with an at least two-fold increase of EFA after venous occlusion (n = 76), poor responders with a lesser increase of EFA due to deficient release of t-PA (n = 12), and poor responders with a normal t-PA release but an increased level of PA-Inhibitor (n = 32). The poor responders due to deficient t-PA release (10% of total) had a higher incidence of recurrence of deep vein thrombosis, than the other groups (p less than 0.01). An overall correlation was found between the level of PA-Inhibitor activity and the triglyceride level (r = 0.40, p less than 0.01), suggesting that these elevations may be due to a common cause, at least in some of the patients. It is concluded that a poor fibrinolytic response to venous occlusion occurs in 35 percent of DVT patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and OutcomesMedicineDeep veinPlasminogen activatorThrombosisProtein CInternal medicineAntithrombinGastroenterologyVenous thrombosisPlasminogen activator inhibitor-1

MeSH terms

AdultAgedFemaleFibrinolysisGlycoproteinsHumansMaleMiddle AgedTissue Plasminogen ActivatorSerum GlobulinsThrombophlebitisTriglyceridesPlasminogen Inactivators
Citations
367
FWCI
16.87
field-weighted impact
References
0
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.